Form 4: Flora Growth CFO's Stock Appreciation Rights Repriced Lower Following Shareholder Approval

Flora Growth Corp.'s Chief Financial Officer, Dany Vaiman, had his Stock Appreciation Rights (SARs) repriced to a lower exercise price with shareholder approval, as detailed in a recent SEC Form 4 filing.

Summary

• Dany Vaiman, Chief Financial Officer of Flora Growth Corp. (FLGC), reported changes in his beneficial ownership of Stock Appreciation Rights (SARs) on June 30, 2025.
• SARs originally granted on December 15, 2023, August 14, 2024, and December 15, 2024, were amended to have a lower exercise price following shareholder approval.
• Specifically, 342,888 SARs with an original exercise price of $1.21 were effectively replaced by SARs with an exercise price of $0.58.
• Additionally, 191,773 SARs with an original exercise price of $0.915 were replaced by SARs with an exercise price of $0.58.
• Furthermore, 372,500 SARs with an original exercise price of $1.30 were replaced by SARs with an exercise price of $0.58.
• The total number of SARs held by the CFO following these transactions is 907,161 (342,888 + 191,773 + 372,500) with a new exercise price of $0.58.
• These SARs are structured to vest in 8 equal installments, subject to specific stock price criteria being met prior to each tranche vesting, and have a post-termination exercise period of one year.

Sentiment

Score: 3

Explanation: The repricing of executive Stock Appreciation Rights (SARs) to a lower exercise price, while approved by shareholders, is generally viewed negatively by the market as it often signals past underperformance and makes it easier for executives to realize value from their compensation, potentially at the expense of existing shareholders.

Positives

• Shareholder approval was obtained for the amendment of the Stock Appreciation Rights (SARs), indicating adherence to corporate governance procedures.
• The repricing of SARs to a lower exercise price may re-incentivize the CFO by making the compensation more attainable, potentially aligning their interests with future stock price appreciation from the new lower base.

Negatives

• The repricing of executive Stock Appreciation Rights (SARs) to a significantly lower exercise price (from original prices of $1.21, $0.915, and $1.30 down to $0.58) typically occurs when the company's stock performance has been poor, making the original grants less valuable or out-of-the-money.
• This repricing effectively makes it easier for the CFO to realize value from their compensation, potentially at the expense of existing shareholders who may have seen their investment decline.
• Such repricing can be viewed negatively by investors as it may signal a lack of confidence in the company's ability to reach higher stock price targets or as a dilution of shareholder value.

Risks

• Potential for negative investor sentiment regarding executive compensation practices, particularly the repricing of Stock Appreciation Rights (SARs) to a lower exercise price, which can be perceived as rewarding management despite underperformance.
• Risk of shareholder dissatisfaction or scrutiny over corporate governance related to executive incentive plans.

Future Outlook

The Stock Appreciation Rights (SARs) are structured to vest in 8 equal installments, contingent upon the achievement of specific stock price criteria prior to each tranche vesting. The SARs also include a post-termination exercise period of one year.

Management Comments

• Management indicated that the Stock Appreciation Rights (SARs) granted on December 15, 2023, August 14, 2024, and December 15, 2024, were amended to a lower exercise price, a change that received shareholder approval.

Industry Context

The repricing of executive compensation, such as Stock Appreciation Rights (SARs), is a practice sometimes observed in industries where companies face significant stock price volatility or sustained periods of underperformance. It aims to re-incentivize executives when original equity awards become significantly out-of-the-money, though it can be viewed critically by investors concerned about dilution or rewarding management for poor performance. This practice is not uncommon in growth-oriented or emerging industries, like the cannabis sector where Flora Growth operates, which can experience rapid market shifts and investor sentiment changes.

Comparison to Industry Standards

• Repricing of executive equity awards, while not ideal, is a practice seen across various industries, particularly in sectors experiencing significant market downturns or where initial performance targets were overly ambitious. For instance, during the dot-com bust or the 2008 financial crisis, many companies, including established tech firms and financial institutions, repriced options to retain talent.
• In the cannabis industry, which has faced regulatory hurdles and market volatility, similar repricing events have occurred at companies like Canopy Growth (CGC) or Aurora Cannabis (ACB) when their stock prices significantly declined, making original grants less effective as incentives.
• The specific exercise price of $0.58 for the SARs would need to be compared against the current trading price of FLGC and the average exercise prices of similar executive awards at peer companies within the cannabis or consumer goods sector to fully assess its competitiveness and fairness.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential negative impact due to the repricing of executive compensation, which can be perceived as dilutive or as rewarding management despite underperformance, potentially affecting investor confidence and share price.
• CFO (Dany Vaiman): Positive impact as the lower exercise price makes the Stock Appreciation Rights (SARs) more attainable and increases the likelihood of realizing value from the compensation.

Next Steps

• The Stock Appreciation Rights (SARs) will vest in 8 equal installments.
• Vesting is subject to specific stock price criteria that must be met prior to each tranche vesting.
• The SARs have a post-termination exercise period of one year.

Key Dates

Recommendation

Keywords

Flora Growth Corp., FLGC, SEC Form 4, Stock Appreciation Rights, SARs, Executive Compensation, Dany Vaiman, CFO, Repricing, Shareholder Approval, Derivative Securities, Beneficial Ownership